Replies to post #251416 on Biotech Values

[mouton29]

Re: Ocular Therapeutix Paxtrava. Here’s a link to the presentation. Efficacy looks good, not so sure about the side effects. https://investors.ocutx.com/static-files/7d4551c6-1158-4a4b-a13a-2198a210de00

[iwfal]

OCUL Glaucoma

FWIW - both glaucoma inserts on the market, the second having just been approved, have a label restriction disallowing use more than once in an eye. For at least Durysta this was not the original plan; it just showed up in the later/bigger trials that repeated use showed problems. My point is that this was not obvious in the earlier/smaller trials that are more like this OCUL one, and I haven’t yet seen strong data on what small trial, single use proxies accurately predict that reuse risk in the later ph3.